HK Stock Market Move | GENSCRIPT BIO (01548) surged over 4%, with AIDD-related business doubling year-on-year in the first half of the year.

GENSCRIPT BIO (01548) rose over 4%, and as of the time of publication, it was up 4.18%, trading at HKD 25.92, with a turnover of HKD 757 million. On the news front, GENSCRIPT BIO announced its interim results for the six months ending June 30, 2026. In the first half of this year, the company achieved a revenue of approximately USD 404 million, a year-on-year increase of 27.3%; the gross profit was about USD 207 million, up 48.0%; and the adjusted net profit was approximately USD 62.5 million, marking a year-on-year increase of 203.3%. During the reporting period, the revenue from the Life Sciences segment was approximately USD 319 million, reflecting a year-on-year growth of 28.8%; the adjusted operating profit was about USD 94 million, a year-on-year increase of approximately 102.8%. The company attributed this mainly to structural growth driven by AI-driven drug discovery and the increasing market demand for "gene-to-protein" integrated solutions. It is noteworthy that Genscript's globally leading gene-to-protein platform business accounted for about 66% of the revenues in the Life Sciences segment, continuing to be an important pillar of business growth. During the reporting period, the AIDD-related business achieved a year-on-year doubling of growth and maintained a rapid growth trend for three consecutive halves. The company stated that as its cooperation with leading global AI pharmaceutical companies deepens, it is further solidifying its competitive advantage as an industry-leading wet lab validation platform, expecting that the revenue from AIDD-related orders will continue to maintain a doubling growth trend in the future.